MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: adam hefian who wrote (1077)	7/17/1998 7:30:00 AM
From: David Cathcart	Read Replies (1) of 1826

Adam, As R.B. points out, MGI Pharma is heading into phase II with MGI 114 this month. They are ready now and are actively enrolling patients. Actual dosing will start any day. The announcement of entering phase II will not necessarily have an immediate effect on the price of MOGN. The market knows about it now. But any announcement from the company should cause additional investors to look at the company. If those investors happen to be institutional investors, and if they like what they see, you may get what you are looking for. Chances are we will not hear any results of phase II trials for at least five months, or not until well into the fourth quarter. During the conference call John MacDonald said that each patient would receive four dosing regimens and each regimen last 28 days. At the end of the four regimens they will analyze the data. Then we may hear something. For the present quarter, Salagen sales will be the driving force. We could also get an announcement of a Euro partner for MGI 114, but for that to happen negotiations may have to take place on the Riviera. I volunteer to be on the negotiating team, but I'm gonna wear big ol' swim trunks. David

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next